The Economic Times
12,248.2567.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Strides Pharma gets tentative nod from USFDA for pain relieving drug

Strides Pharma Global Pte Ltd, Singapore, has received tentative approval for Diclofenac Potassium Softgel Capsules, 25 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

PTI|
Updated: Dec 04, 2019, 12.17 PM IST
0Comments
Agencies
pharma
The product is a generic version of Zipsor Capsules in the strength of 25 mg, of Assertio Therapeutics, Inc.
NEW DELHI: Drug firm Strides Pharma Science on Wednesday said it has got tentative approval from US health regulator for Diclofenac Potassium Softgel Capsules a drug used to relieve pain.

Strides Pharma Global Pte Ltd, Singapore, has received tentative approval for Diclofenac Potassium Softgel Capsules, 25 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

Strides Pharma Global Pte Ltd is a step-down wholly owned subsidiary of Strides Pharma Science.

The product is a generic version of Zipsor Capsules in the strength of 25 mg, of Assertio Therapeutics, Inc.

Diclofenac Potassium Softgel Capsule is a nonsteroidal anti-Inflammatory drug used to relieve pain and swelling. It is used to treat muscle aches, backaches, dental pain, menstrual cramps, and sports injuries.

Diclofenac Potassium Softgel Capsules is part of Strides niche and small volume product portfolio with limited competition in the US market.

According to IQVIA MAT data, the US market for Diclofenac Potassium Softgel Capsules, 25 mg is approximately USD 30 million.

Strides can launch the product earliest by September 2022 based on terms of settlement.

On receiving full approval, the product will be manufactured at the company's Oral dosage facility in Bengaluru and marketed by Strides Pharma Inc in the US Market.

Shares of Strides Pharma Science were trading at Rs 381.40, higher by 1.31 per cent on BSE.

Also Read

USFDA inspects Alembic Pharma's facility in Karkhadi, Gujarat

Cipla announces closure of USFDA inspection at Patalganga facility

Strides gets USFDA nod for anti-allergic drug

Aurobindo Pharma tanks on USFDA observations

Lupin gets USFDA nod to market skin ointment

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service